ELTP · Elite Pharmaceuticals Inc /Nv/
The latest filing no longer states the doubt (first flagged Jun 29, 2026).
View the 10-Q filed Aug 13, 2026Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q3 FY26 earnings call · Feb 18, 2026TL;DR. Elite Pharmaceuticals reported Q3 FY2026 revenue of $31.6 million (up 120% year-over-year), pushing nine-month revenue to $108 million and surpassing prior-year full-year revenue of $84 million. Operating income surged 721% to $9 million for the quarter, operating cash flow rose 313% to $14.6 million, and working capital grew to $84 million, while the CEO guided to $130–140 million for the full year and reiterated M&A as the top priority.
- + Quarterly operating income jumped 721% to $9 million and nine-month operating income rose 361% to $39 million
- + Gross profit grew 112% to $13 million for the quarter and 138% to $54 million for nine months, with margins recovering from September one-time fees
- + Management projects full-year FY2026 revenue of approximately $130–140 million
- + Generic lisdexamfetamine holds roughly 70% market share and the company is awaiting OxyContin ER (paragraph IV) and methadone launches to expand the pipeline
- − Generic lisdexamfetamine pricing has fallen to roughly half of early-year levels, reducing profit per bottle
- − Inventory grew at quarter-end due to late-December shipments and raw materials not recognized until delivered
- − OxyContin ER (paragraph IV) ANDA litigation is on stay pending Purdue/NOAA action, delaying any launch
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ELTP
this stock
Elite Pharmaceuticals Inc /Nv/
|
$276.61M | -45.9% | +41.0% | 5.1 | 0.2% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$59.16B | +18.8% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$45.83B | -5.0% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.74B | +25.8% | +4.3% | 64.3 | 2.7% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$41.48B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 0.0%
- Net QoQ
- +500 sh
- Top holder
- KELLEHER FINANCIAL ADVISO…
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ELTP | +16.7% | +6.0% | -30.3% | +9.6% | -45.9% |
| SPY | +1.3% | +2.1% | +9.0% | +1.5% | +13.5% |
| vs SPY | +15.4% | +3.9% | -39.2% | +8.1% | -59.4% |